TerrAscend (TSNDF) Cash from Discontinued Operations (2022 - 2026)
TerrAscend (TSNDF) reported Cash from Discontinued Operations of 165000.0 for Q1 2026, up 94.8% year-over-year from 84701.6 in Q1 2025, and up 47.28% quarter-over-quarter from 313000.0 in Q4 2025.
TerrAscend (TSNDF) Cash from Discontinued Operations (2022 - 2026) Analysis & Trends
TerrAscend (TSNDF) has 5 years of Cash from Discontinued Operations data on file, last reported at 165000.0 in Q1 2026.
- Cash from Discontinued Operations for Q1 2026 came in at 165000.0, up 94.8% year-over-year; the trailing twelve-month figure through Mar 2026 was 9389000.0 (up 17.93% YoY), and the FY2025 annual result was 12398000.0, down 49.99% from the prior year.
- Cash from Discontinued Operations advanced to 165000.0 in Q1 2026 per TSNDF's latest filing, from 313000.0 in the prior quarter.
- Over five years, Cash from Discontinued Operations peaked at 2956000.0 in Q4 2024 and troughed at 20757000.0 in Q4 2023.
- A 5-year average of 3095875.0 and a median of 1646500.0 in 2022 frame the typical range for Cash from Discontinued Operations.
- The sharpest annual moves came in 2023 and 2024: Cash from Discontinued Operations tumbled 9378.08% in 2023, then jumped 114.24% in 2024.
- A 5-year view of Cash from Discontinued Operations shows it stood at 219000.0 in 2022, then plunged by 9378.08% to 20757000.0 in 2023, then jumped by 114.24% to 2956000.0 in 2024, then sank by 110.59% to 313000.0 in 2025, then surged by 47.28% to 165000.0 in 2026.
- Business Quant data shows TSNDF's Cash from Discontinued Operations at 165000.0 in Q1 2026, 313000.0 in Q4 2025, and 4427000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | - |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | - |
| 10 | TerrAscend | - | - | 34.60 Mn | -165,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -165,000.00 |
| Mar 31, 2026 | -165,000.00 |
| Dec 31, 2025 | -313,000.00 |
| Dec 31, 2025 | -313,000.00 |
| Sep 30, 2025 | -4.43 Mn |
| Sep 30, 2025 | -4.43 Mn |
| Jun 30, 2025 | -4.48 Mn |
| Jun 30, 2025 | -4.48 Mn |
| Mar 31, 2025 | -3.17 Mn |
| Mar 31, 2025 | -3.17 Mn |
| Dec 31, 2024 | 2.96 Mn |
| Dec 31, 2024 | 2.96 Mn |
| Sep 30, 2024 | -4.05 Mn |
| Sep 30, 2024 | -4.05 Mn |
| Jun 30, 2024 | -7.18 Mn |
| Jun 30, 2024 | -7.18 Mn |
| Dec 31, 2023 | -20.76 Mn |
| Dec 31, 2023 | -20.76 Mn |
| Sep 30, 2023 | -496,000.00 |
| Sep 30, 2023 | -496,000.00 |